John Orwin tapped to lead Atreca; John Tsai takes Vas Narasimhan's old role at Novartis; Hal Barron nabs Genentech's Kevin Sin
→ Atreca co-founder Tito Serafini is passing the reins to newly installed CEO John Orwin, electing instead to spend his time on the new chief strategy officer role he created for himself. Serafini has a broad mandate over research, preclinical development, technology and intellectual property at the biotech, which is focused on harnessing the human immune response for next-gen immuno-oncology drugs. Now that he’s built upon the concept and established a slate of preclinical assets with a proprietary discovery engine — including a lead candidate ready for IND in mid-2019 — the board thinks it’s time to bring in someone to scale the company up. With his experience leading biotechs Relypsa and Affymax as well as working for giants like J&J and Genentech, Orwin strikes them as the right partner for Serafini.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.